RESUMO
RATIONALE & OBJECTIVE: Frailty is common in individuals with chronic kidney disease (CKD) and increases the risk of adverse outcomes in adults with kidney failure requiring dialysis. However, this relationship has not been thoroughly evaluated among those with non-dialysis-dependent CKD. STUDY DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: 2,539 adults in the Chronic Renal Insufficiency Cohort Study. EXPOSURE: Frailty status assessed using 5 criteria: slow gait speed, muscle weakness, low physical activity, exhaustion, and unintentional weight loss. OUTCOME: Atherosclerotic events, incident heart failure, all-cause death, and cardiovascular death. ANALYTICAL APPROACH: Cause-specific hazards models. RESULTS: At study entry, the participants' mean age was 62 years, 46% were female, the mean estimated glomerular filtration rate was 45.4mL/min/1.73m2, and the median urine protein was 0.2mg/day. Frailty status was as follows: 12% frail, 51% prefrail, and 37% nonfrail. Over a median follow-up of 11.4 years, there were 393 atherosclerotic events, 413 heart failure events, 497 deaths, and 132 cardiovascular deaths. In multivariable regression analyses, compared with nonfrailty, both frailty and prefrailty status were each associated with higher risk of an atherosclerotic event (HR, 2.03 [95% CI, 1.41-2.91] and 1.77 [95% CI, 1.35-2.31], respectively) and incident heart failure (HR, 2.22 [95% CI, 1.59-3.10] and 1.39 [95% CI, 1.07-1.82], respectively), as well as higher risk of all-cause death (HR, 2.52 [95% CI, 1.84-3.45] and 1.76 [95% CI, 1.37-2.24], respectively) and cardiovascular death (HR, 3.01 [95% CI, 1.62-5.62] and 1.78 [95% 1.06-2.99], respectively). LIMITATIONS: Self-report of aspects of the frailty assessment and comorbidities, which may have led to bias in some estimates. CONCLUSIONS: In adults with CKD, frailty status was associated with higher risk of cardiovascular events and mortality. Future studies are needed to evaluate the impact of interventions to reduce frailty on cardiovascular outcomes in this population. PLAIN-LANGUAGE SUMMARY: Frailty is common in individuals with chronic kidney disease (CKD) and increases the risk of adverse outcomes. We sought to evaluate the association of frailty status with cardiovascular events and death in adults with CKD. Frailty was assessed according to the 5 phenotypic criteria detailed by Fried and colleagues. Among 2,539 participants in the CRIC Study, we found that 12% were frail, 51% were prefrail, and 37% were nonfrail. Frailty status was associated with an increased risk of atherosclerotic events, incident heart failure, and death.
Assuntos
Aterosclerose , Fragilidade , Insuficiência Cardíaca , Insuficiência Renal Crônica , Adulto , Humanos , Feminino , Pessoa de Meia-Idade , Masculino , Estudos de Coortes , Estudos Prospectivos , Fragilidade/epidemiologia , Fragilidade/complicações , Insuficiência Renal Crônica/complicações , Insuficiência Renal Crônica/epidemiologia , Insuficiência Cardíaca/epidemiologia , Insuficiência Cardíaca/complicações , Aterosclerose/epidemiologia , Aterosclerose/etiologiaRESUMO
Background: Several cardiac biomarkers of cardiac stress, inflammation, and fibrosis (N-terminal pro brain-type natriuretic peptide [NT-proBNP], high-sensitivity troponin T [hsTnT], growth differentiation factor 15 [GDF-15], and soluble ST2 [sST2]) have been associated with atherosclerotic disease in the general population. We hypothesized that these cardiac biomarkers may also be associated with the atherosclerotic cardiovascular disease in patients with CKD. Methods: We analyzed levels of NT-proBNP, hsTnT, GDF-15, and sST2 in a cohort of 2732 participants with mild to moderate CKD from the Chronic Renal Insufficiency Cohort (CRIC) study. Outcomes included incident atherosclerotic disease, defined as the first instance of myocardial infarction, stroke, or peripheral vascular disease. We used Cox proportional hazard models to the test the association of each cardiac biomarker with risk of incident atherosclerotic disease, adjusting for multiple possible confounders. Results: When modeled continuously (per SD increase in the log-transformed biomarker), NT-proBNP, hsTnT, GDF-15, and sST2 were significantly associated with incident atherosclerotic disease after adjustment for multiple potential confounders: (NT-proBNP HR, 1.51; 95% CI, 1.27 to 1.81; hsTnT HR, 1.61; 95% CI, 1.38 to 1.89; GDF-15 HR, 1.44; 95% CI, 1.19 to 1.73; and sST2 HR, 1.19; 95% CI, 1.04 to 1.36). Conclusions: NT-proBNP, hsTnT, GDF-15, and sST2 were significantly associated with incident atherosclerotic cardiovascular disease in patients with CKD. These associations may highlight important mechanisms for the development of atherosclerotic disease in CKD.
Assuntos
Aterosclerose , Doenças Cardiovasculares , Insuficiência Renal Crônica , Aterosclerose/diagnóstico , Biomarcadores , Doenças Cardiovasculares/diagnóstico , Fator 15 de Diferenciação de Crescimento , Humanos , Proteína 1 Semelhante a Receptor de Interleucina-1 , Insuficiência Renal Crônica/diagnóstico , Troponina TAssuntos
Benzoxazinas/efeitos adversos , Cálculos Renais/induzido quimicamente , Inibidores da Transcriptase Reversa/efeitos adversos , Idoso , Alcinos , Benzoxazinas/uso terapêutico , Ciclopropanos , Infecções por Escherichia coli/tratamento farmacológico , Infecções por HIV/tratamento farmacológico , Humanos , Masculino , Inibidores da Transcriptase Reversa/uso terapêutico , Estados Unidos , Infecções Urinárias/tratamento farmacológicoRESUMO
We report the case of a 28-year-old man with systemic lupus erythematosus (SLE) and rapidly progressive glomerulonephritis (RPGN) due to fibrillary glomerulonephritis (FGN). The patient had a history of SLE and had been treated with mycophenolate mofetil, prednisone, and intravenous cyclophosphamide for his renal and extra-renal manifestations. In spite of this treatment, he developed RPGN. A subsequent renal biopsy revealed diffuse proliferative glomerulonephritis with fibrillary deposits. SLE is rarely associated with FGN, however FGN should be considered in the differential diagnosis of any SLE patient with RPGN.
Assuntos
Glomerulonefrite/imunologia , Glomerulonefrite/patologia , Lúpus Eritematoso Sistêmico/complicações , Adulto , Progressão da Doença , Glomerulonefrite/complicações , Humanos , Falência Renal Crônica/terapia , Masculino , Microscopia EletrônicaRESUMO
We present evidence that Na-K-ATPase in the rat proximal tubule is directly activated by ANG II much faster than previously observed. Specifically, we show that a 2-min exposure to 0.1 and 1 nM ANG II slowed the rate of intracellular sodium accumulation in response to an increase in extracellular sodium added in the presence of gramicidin D. From these data, we show that ANG II directly stimulates Na-K-ATPase activity at rate-limiting concentrations of intracellular sodium. Under these same conditions, exposing proximal tubules to ANG II altered the amount of 32P incorporated into multiple phosphopeptides generated from a tryptic digest of the alpha-subunit of Na-K-ATPase. Na-K-ATPase was isolated from whole cell lysates by means of a ouabain-affinity column and then separated into its individual subunits by SDS-PAGE. Na-K-ATPase bound to the column in its E2 conformation and was eluted by altering its conformation to E1 using Na+ATP. Na-K-ATPase isolated from cells treated with ANG II eluted more easily from the ouabain-affinity column than Na-K-ATPase isolated from control cells, suggesting that ANG II decreased the affinity of Na-K-ATPase for ouabain. Thus ANG II rapidly stimulated the activity of Na-K-ATPase in 2 min or less by a mechanism that could involve changes in phosphorylation and conformation of Na-K-ATPase. We suggest that the physiological role for rapid direct activation of Na-K-ATPase is greater control of intracellular sodium during sodium reabsorption.
Assuntos
Angiotensina II/farmacologia , Túbulos Renais Proximais/efeitos dos fármacos , Túbulos Renais Proximais/enzimologia , ATPase Trocadora de Sódio-Potássio/metabolismo , Vasoconstritores/farmacologia , Animais , Inibidores Enzimáticos/metabolismo , Inibidores Enzimáticos/farmacologia , Hipertensão Renal/metabolismo , Masculino , Ouabaína/metabolismo , Ouabaína/farmacologia , Fosforilação/efeitos dos fármacos , Ratos , Ratos Sprague-Dawley , Sódio/metabolismoRESUMO
Various mechanical stimuli increase the intracellular Ca(2+) concentration ([Ca(2+)](i)) in vascular smooth muscle cells (VSMC). A part of the increase in [Ca(2+)](i) is due to the release of Ca(2+) from intracellular stores. We have investigated the effect of mechanical stimulation produced by cyclical stretch on the release of Ca(2+) from the intracellular stores. Permeabilized VSMC loaded with (45)Ca(2+) were subjected to 7.5% average (15% maximal) cyclical stretch. This resulted in an increase in (45)Ca(2+) rate constant by 0.126 +/- 0.0035. Inhibition of inositol 1,4,5-trisphosphate (IP(3)), ryanodine, and nicotinic acid adenine dinucleotide phosphate channels (NAADP) with 50 microg/ml heparin, 50 microM ruthenium red, and 25 microM thio-NADP, respectively, did not block the increase in (45)Ca(2+) efflux in response to cyclical stretch. However, 10 microM lanthanum, 10 microM gadolinium, and 10 microM cytochalasin D but not 10 microM nocodazole inhibited the increase in (45)Ca(2+) efflux. This supports the existence of a novel stretch-sensitive intracellular Ca(2+) store in VSMC that is distinct from the IP(3)-, ryanodine-, and NAADP-sensitive stores.